BioMark Diagnostics Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rashid Ahmed Maula Bux
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3851 Shell Road Richmond BC Canada V6X 2W2
- IPO Date
- Mar 23, 2015
- Website
- biomarkdiagnostics.com
- Similar Companies
- Business
- BioMark Diagnostics Inc. (CSE: BUX; FSE: 20B; OTCQB: BMKDF) develops advanced liquid biopsy diagnostic technologies leveraging metabolomics and machine learning for early-stage cancer detection, monitoring, treatment response assessment, and cancer survivorship screening; its core platform focuses on non-invasive blood-based assays targeting hard-to-detect cancers including lung, glioblastoma, gastrointestinal, prostate, head, and neck cancers, with specific emphasis on biomarkers such as Spermidine/spermine N-acetyltransferase 1 (SSAT1) and high-powered metabolic panels for early lung cancer diagnosis. The company, founded in 2014 and headquartered at 130-3851 Shell Road, Richmond, British Columbia, Canada, operates primarily in Canada with expansion efforts into the United States, Europe, North Africa, China, and Japan; it provides diagnostic and research services to pharmaceutical and biotechnology clients while advancing commercialization of its oncology solutions for oncologists, healthcare providers, and clinical programs. Recent developments include a strategic laboratory equipment leasing agreement in August 2025 doubling testing capacity to support the imminent commercial launch of its lung cancer assay and expansion of specialty laboratory services in Quebec; uplisting to OTCQB in May 2025; grant of patents for its lung cancer detection platform in China and Japan in September 2025; collaborations such as the HANSE lung cancer screening trial in Germany in October 2025, an Expression of Interest with SAMA Consulting for North Africa in August 2025, and a Quebec lung cancer screening project with AstraZeneca Canada, Pfizer Canada, and IUCPQ-UL awarded the ADRIQ Innovation Award in November 2025; publications validating its plasma metabolite markers and AI graph neural networks for lung cancer in May 2025; and a CAD $4.26 million private placement in fiscal year 2025 alongside ongoing discussions for non-dilutive funding and partnerships.
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark: 2025 Achievements & 2026 Vision
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
BioMark Diagnostics using biomarkers for early cancer detection to save lives, healthcare resources
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
BioMark Announces the Final Closing of Oversubscribed Private Placement
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN